Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis

The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professionals who...

Descripción completa

Detalles Bibliográficos
Autores principales: de Natividade, Natallia Barreiros, Felix, Paulo Antonio Oldani, Lerer, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726687/
https://www.ncbi.nlm.nih.gov/pubmed/29267456
http://dx.doi.org/10.1590/abd1806-4841.20175871
Descripción
Sumario:The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professionals who prescribe biologic drugs. We also stress the importance of investigating the past and family medical history regarding demyelinating diseases before starting treatment.

Ejemplares similares